Cargando…

Effects of transplantation-related immunosuppression on co-existent neuroendocrine tumours

BACKGROUND: Here we detail our experience of managing patients found to have a neuroendocrine neoplasm (NEN) whilst on immunosuppression for a transplanted organ. AIM: We aimed to quantify the behaviour of NENs under solid-organ transplant-related immunosuppression. DESIGN: This was an observational...

Descripción completa

Detalles Bibliográficos
Autores principales: Shah, H A, Faulkes, R, Coldham, C, Shetty, S, Shah, T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9737287/
https://www.ncbi.nlm.nih.gov/pubmed/35143660
http://dx.doi.org/10.1093/qjmed/hcac036
_version_ 1784847248411066368
author Shah, H A
Faulkes, R
Coldham, C
Shetty, S
Shah, T
author_facet Shah, H A
Faulkes, R
Coldham, C
Shetty, S
Shah, T
author_sort Shah, H A
collection PubMed
description BACKGROUND: Here we detail our experience of managing patients found to have a neuroendocrine neoplasm (NEN) whilst on immunosuppression for a transplanted organ. AIM: We aimed to quantify the behaviour of NENs under solid-organ transplant-related immunosuppression. DESIGN: This was an observational, retrospective case series. METHODS: Ten patients were identified from a prospectively kept database. Three were excluded. RESULTS: Four patients received a liver, two a kidney, and one a heart transplant. All but one received calcineurin-based immunosuppression. NENs were found in five patients post-transplant: one had surgery for transverse colonic neuroendocrine carcinoma NEC (pT4N1M0, Ki67 60%), was cancer-free after four years; one had cold biopsy of duodenal NEN (pT1N0M0, Ki67 2%), cancer-free at four months; one 7 mm pancreatic NEN (pT1N0M0), untreated and stable for seven years; one small-bowel NEN with mesenteric metastasis (pTxNxM1), alive four years after diagnosis; and one untreated small-bowel NEN with mesenteric metastasis, stable at 1 year after liver transplantation. Two NENs were discovered pre-transplant, one pancreatic NEN (pT1N0M0, Ki67 5%), remains untreated and stable at three years. One gastric NEN (type 3, pT1bN0M0, Ki67 2%) remains stable without treatment for two years. CONCLUSIONS: NENs demonstrate indolent behaviour in the presence of transplant-related immunosuppression.
format Online
Article
Text
id pubmed-9737287
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-97372872022-12-13 Effects of transplantation-related immunosuppression on co-existent neuroendocrine tumours Shah, H A Faulkes, R Coldham, C Shetty, S Shah, T QJM Original Papers BACKGROUND: Here we detail our experience of managing patients found to have a neuroendocrine neoplasm (NEN) whilst on immunosuppression for a transplanted organ. AIM: We aimed to quantify the behaviour of NENs under solid-organ transplant-related immunosuppression. DESIGN: This was an observational, retrospective case series. METHODS: Ten patients were identified from a prospectively kept database. Three were excluded. RESULTS: Four patients received a liver, two a kidney, and one a heart transplant. All but one received calcineurin-based immunosuppression. NENs were found in five patients post-transplant: one had surgery for transverse colonic neuroendocrine carcinoma NEC (pT4N1M0, Ki67 60%), was cancer-free after four years; one had cold biopsy of duodenal NEN (pT1N0M0, Ki67 2%), cancer-free at four months; one 7 mm pancreatic NEN (pT1N0M0), untreated and stable for seven years; one small-bowel NEN with mesenteric metastasis (pTxNxM1), alive four years after diagnosis; and one untreated small-bowel NEN with mesenteric metastasis, stable at 1 year after liver transplantation. Two NENs were discovered pre-transplant, one pancreatic NEN (pT1N0M0, Ki67 5%), remains untreated and stable at three years. One gastric NEN (type 3, pT1bN0M0, Ki67 2%) remains stable without treatment for two years. CONCLUSIONS: NENs demonstrate indolent behaviour in the presence of transplant-related immunosuppression. Oxford University Press 2022-02-10 /pmc/articles/PMC9737287/ /pubmed/35143660 http://dx.doi.org/10.1093/qjmed/hcac036 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the Association of Physicians. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Papers
Shah, H A
Faulkes, R
Coldham, C
Shetty, S
Shah, T
Effects of transplantation-related immunosuppression on co-existent neuroendocrine tumours
title Effects of transplantation-related immunosuppression on co-existent neuroendocrine tumours
title_full Effects of transplantation-related immunosuppression on co-existent neuroendocrine tumours
title_fullStr Effects of transplantation-related immunosuppression on co-existent neuroendocrine tumours
title_full_unstemmed Effects of transplantation-related immunosuppression on co-existent neuroendocrine tumours
title_short Effects of transplantation-related immunosuppression on co-existent neuroendocrine tumours
title_sort effects of transplantation-related immunosuppression on co-existent neuroendocrine tumours
topic Original Papers
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9737287/
https://www.ncbi.nlm.nih.gov/pubmed/35143660
http://dx.doi.org/10.1093/qjmed/hcac036
work_keys_str_mv AT shahha effectsoftransplantationrelatedimmunosuppressiononcoexistentneuroendocrinetumours
AT faulkesr effectsoftransplantationrelatedimmunosuppressiononcoexistentneuroendocrinetumours
AT coldhamc effectsoftransplantationrelatedimmunosuppressiononcoexistentneuroendocrinetumours
AT shettys effectsoftransplantationrelatedimmunosuppressiononcoexistentneuroendocrinetumours
AT shaht effectsoftransplantationrelatedimmunosuppressiononcoexistentneuroendocrinetumours